huPBMC-(M-NSG)

品系全名

huPBMC-(M-NSG)

目录号

NM-NSG-015

品系状态

活体

导出PDF

基因信息

基因名
IL2RG

基因曾用名

gc; p64; [g]c; CD132; gamma(c)

NCBI ID

16186

MGI ID

96551

Ensembl ID

ENSMUSG00000031304

Pubmed

IL2RG

人类同源基因

IL2RG

品系描述

PBMC人源化（hPBMC）小鼠是用来进行传染病、GvHD及肿瘤免疫的有效模型。人源PBMC中的T细胞受到小鼠异种抗原刺激而增殖，其他类型细胞则维持较低含量或过早消亡。PBMC人源化小鼠体内的人源细胞以T细胞为主，适合需要T细胞免疫反应的各类研究。但T细胞也会对受体小鼠进行过度免疫攻击，进而引发移植物抗宿主病（GvHD），并可在数周之后引起小鼠死亡。所以PBMC人源化小鼠可供实验的窗口期较短，只适合于短期性研究。在M-NSG-B2m小鼠基础上构建的PBMC人源化小鼠剔除了MHC class I分子的β亚基基因B2M，将可延缓人源免疫细胞对宿主的攻击，延长实验窗口期。
应用领域：肿瘤免疫研究；血液病研究；感染疾病研究；基因治疗；无交叉反应的药物靶点研究；免疫原性试验

验证数据

表型分析

image.png

01a8e1ea-fa0a-4081-94ea-cfd8ab4e60dc.png

Fig. Flow analysis of peripheral blood lymphocyte subpopulations in the Hu-PBMC model. Human PBMCS (5E6) was injected intravenously into M-NSG mice (female, 6 weeks old, n=6). Blood was taken at different time points after implantation of humanPBMCS for flow cytometric analysis.

药效评价

基于肠癌Hu-PBMC模型的抗肿瘤药效验证

f9821b8e-5b91-40cc-9900-e61c4cf1a07d.png

Fig. In vivo pharmacodynamic studies using the Hu-PBMC model of intestinal cancer (HT29).


基于人小细胞肺癌Hu-PBMC模型的双抗药物抗肿瘤药效验证

0aa269e4-f076-4e41-b973-db371dd39a53.png

Fig. In vivo efficacy studies using the human small cell lung cancer (SHP-77) Hu-PBMC model.


基于人结直肠癌Hu-PBMC模型的CAR-NK疗法抗肿瘤药效验证

0c1b82b6-01f6-4c31-b753-62a7120b1bb6.png

Fig. In vivo CAR-NK efficacy study using the human colorectal cancer (LoVo) Hu-PBMC model.


发表文献 2篇

1. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment
发表年份：2024 来源杂志：CELL

2. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors
发表年份：2023 来源杂志：Cancer Communications

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看